How returning regulatory T cells help the thymus balance immunity and prevent autoimmunity
Regulation of central tolerance and Treg development by recirculating Treg
This project looks at whether a special group of regulatory T cells that travel back to the thymus help prevent autoimmune reactions while keeping protection against infections and cancer strong.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-11332534 on NIH RePORTER |
What this research studies
From a patient's point of view, researchers are focusing on a type of immune cell called regulatory T cells that can move back into the thymus and may change how new immune cells are selected. They will map the different kinds of these returning regulatory T cells and test how each type influences which T cells are kept or diverted during development. The team will use laboratory experiments and model systems to see how these cells affect tolerance to the body's own tissues and responses to tumors or infections. Findings will aim to explain basic immune balance that could guide future patient-focused treatments.
Who could benefit from this research
Good fit: Adults with autoimmune conditions or people interested in contributing blood or tissue samples to immune-tolerance research would be the most relevant candidates to follow or support this work.
Not a fit: Children under 21 and people with conditions unrelated to immune tolerance are unlikely to benefit directly from this project in the near term.
Why it matters
Potential benefit: If true, this work could lead to new ways to prevent or treat autoimmune diseases while preserving vital immune responses to infections and cancer.
How similar studies have performed: Previous laboratory and animal studies have shown that regulatory T cells can control autoimmunity, but applying these findings to safe, effective human treatments is still an early and active area of work.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: Farrar, Michael Archibald — University of Minnesota
- Study coordinator: Farrar, Michael Archibald
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.